US20220184002A1 - Topical dapsone and dapsone/adapalene compositions and methods for use thereof - Google Patents
Topical dapsone and dapsone/adapalene compositions and methods for use thereof Download PDFInfo
- Publication number
- US20220184002A1 US20220184002A1 US17/654,061 US202217654061A US2022184002A1 US 20220184002 A1 US20220184002 A1 US 20220184002A1 US 202217654061 A US202217654061 A US 202217654061A US 2022184002 A1 US2022184002 A1 US 2022184002A1
- Authority
- US
- United States
- Prior art keywords
- dapsone
- composition
- acne
- compositions
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 139
- MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 title claims abstract description 52
- 229960000860 dapsone Drugs 0.000 title claims abstract description 51
- 238000000034 method Methods 0.000 title claims description 19
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 title abstract description 17
- 229960002916 adapalene Drugs 0.000 title abstract description 17
- 230000000699 topical effect Effects 0.000 title description 7
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 claims abstract description 25
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 claims abstract description 24
- 206010000496 acne Diseases 0.000 claims description 63
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 52
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 24
- 238000011282 treatment Methods 0.000 claims description 23
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 229920001577 copolymer Polymers 0.000 claims description 13
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 12
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 12
- 229960002216 methylparaben Drugs 0.000 claims description 12
- 239000013543 active substance Substances 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 229940127557 pharmaceutical product Drugs 0.000 abstract description 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 39
- 210000003491 skin Anatomy 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 28
- 239000002904 solvent Substances 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 20
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 16
- 229960001484 edetic acid Drugs 0.000 description 16
- 229920002125 Sokalan® Polymers 0.000 description 14
- 229940049638 carbomer homopolymer type c Drugs 0.000 description 13
- 229960004063 propylene glycol Drugs 0.000 description 13
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 12
- 229960001631 carbomer Drugs 0.000 description 12
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- 201000004624 Dermatitis Diseases 0.000 description 11
- 239000000839 emulsion Substances 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 239000002738 chelating agent Substances 0.000 description 10
- 239000003795 chemical substances by application Substances 0.000 description 10
- 208000031513 cyst Diseases 0.000 description 10
- 201000004700 rosacea Diseases 0.000 description 10
- 206010033733 Papule Diseases 0.000 description 9
- 230000003902 lesion Effects 0.000 description 9
- 206010037888 Rash pustular Diseases 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 208000029561 pustule Diseases 0.000 description 8
- 241001303601 Rosacea Species 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 6
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 206010054107 Nodule Diseases 0.000 description 6
- 208000003251 Pruritus Diseases 0.000 description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 6
- 208000010668 atopic eczema Diseases 0.000 description 6
- 239000006071 cream Substances 0.000 description 6
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000002562 thickening agent Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000017520 skin disease Diseases 0.000 description 4
- 229940001584 sodium metabisulfite Drugs 0.000 description 4
- 235000010262 sodium metabisulphite Nutrition 0.000 description 4
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- 241001635598 Enicostema Species 0.000 description 3
- 208000010305 Epidermal Cyst Diseases 0.000 description 3
- 206010020649 Hyperkeratosis Diseases 0.000 description 3
- 208000001126 Keratosis Diseases 0.000 description 3
- 206010027626 Milia Diseases 0.000 description 3
- 241001448624 Miliaria Species 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- 206010036229 Post inflammatory pigmentation change Diseases 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- 206010037083 Prurigo Diseases 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 206010048222 Xerosis Diseases 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 229940051250 hexylene glycol Drugs 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 201000011486 lichen planus Diseases 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 239000004530 micro-emulsion Substances 0.000 description 3
- 239000007908 nanoemulsion Substances 0.000 description 3
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 229940032159 propylene carbonate Drugs 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 3
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- 206010000503 Acne cystic Diseases 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 208000009675 Perioral Dermatitis Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 206010039580 Scar Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004106 citric acid Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 206010040882 skin lesion Diseases 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940126702 topical medication Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- 206010000501 Acne conglobata Diseases 0.000 description 1
- 206010000748 Acute febrile neutrophilic dermatosis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000186427 Cutibacterium acnes Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000001244 Linear IgA Bullous Dermatosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- 206010071368 Psychological trauma Diseases 0.000 description 1
- 206010037575 Pustular psoriasis Diseases 0.000 description 1
- 208000006311 Pyoderma Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 206010040867 Skin hypertrophy Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 208000010265 Sweet syndrome Diseases 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- 201000005485 Toxoplasmosis Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 150000001298 alcohols Chemical group 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000000058 anti acne agent Substances 0.000 description 1
- 230000003255 anti-acne Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124340 antiacne agent Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 208000029631 linear IgA Dermatosis Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N p-hydroxybenzoic acid propyl ester Natural products CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- FWFUWXVFYKCSQA-UHFFFAOYSA-M sodium;2-methyl-2-(prop-2-enoylamino)propane-1-sulfonate Chemical compound [Na+].[O-]S(=O)(=O)CC(C)(C)NC(=O)C=C FWFUWXVFYKCSQA-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940104261 taurate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present embodiments relate generally to compositions useful for treating a variety of dermatological conditions.
- some embodiments relate to dapsone and dapsone/adapalene compositions and methods for use thereof.
- Acne is a group of common skin conditions characterized by the so-called “acneiform” or acne-like skin eruptions, which can be contaminated with bacteria, such as Propionibacterium acnes, and can also be marked by inflammation. Acne tends to occur in the areas of skin where the sebaceous glands are most active, such as the face. Acne is associated with psychological trauma, and, if left untreated, can lead to scar formation and disfigurement.
- Classification and the diagnosis of various acne conditions can be complex, and even contradictory. Given this complexity and unpredictability, medication and other therapies, are often developed on a trial-and-error basis in order to determine the most effective course of treatment for a particular patient.
- the outcome of any particular acne treatment regimen greatly varies from patient to patient, as well as throughout treatment of a particular patient.
- treatment efficacy can be greatly affected by a patient's compliance with the treatment regimen.
- Patient compliance during acne treatment may be influenced by side effects, which, for topical medications, commonly include redness, itching, and skin peeling.
- the complexity of the drug regimen can also negatively affect patient compliance, particularly where two or more different topical medications are prescribed simultaneously.
- compositions for treatment of acne are available. Many of the available compositions include one active agent known to have anti-acne activity. Stability of compositions with multiple anti-acne agents can be problematic. Also, these compositions can be difficult to manufacture.
- compositions and methods used in a treatment of a variety of skin conditions, such as acne, in which topical application is potentially effective are provided herein address these and other needs in the art.
- Dapsone (4,4′-diaminodiphenyl sulfone) is a medicament possessing several beneficial medicinal activities. Dapsone is typically administered as one of the medicinal agents used in the treatment of leprosy. Dapsone and its derivatives are also effective for treatment of bacterial infections, protozoal infections such as malaria, pneumocystis carinii, and plasmonic infections such as toxoplasmosis.
- Dapsone is also useful as an anti-inflammatory agent. It has been used to treat skin diseases characterized by the abnormal infiltration of neutrophils, such as Dermatitis herpetiformis, linear IgA dermatosis, pustular psoriasis, pyoderma gangrenosum, acne vulgaris, and Sweet's Syndrome.
- Topical compositions of dapsone can be problematic.
- Topical compositions may act as drying agents for the skin. They remove essential oils and natural skin softeners from the skin thus causing it to be dry, itch and crack. Inclusion of exogeneous skin emollients, oils and the like, however, causes phase separation and precipitation of dapsone.
- Use of typical emulsifiers does not solve the dapsone precipitation owing to the lowered dapsone solubility and conflicting physical characteristics of the phases of the resulting composition.
- topical compositions including dapsone and methods are needed that would, for example, exhibit improved effectiveness, reduced side effects, or both, when used in a particular patient with a skin condition.
- Such improved topical compositions including dapsone and methods of their uses are also needed to improve treatment of patients with acne or suspected acne.
- the present dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions.
- Some useful compositions include dapsone and/or adapalene in a polymeric viscosity builder.
- Some compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin.
- Diethylene glycol monoethyl ether is a solubilizer for dapsone, thereby allowing compositions to be prepared with increased solubilized concentrations of dapsone.
- the compositions described herein are effective in treating dermatological conditions in a subject in need thereof
- a polymeric viscosity builder minimizes the intensity of yellowing of the composition caused by the increased solubility of dapsone in diethylene glycol monoethyl ether.
- the polymeric viscosity builder influences dapsone crystallization. This, in turn, results in compositions with improved aesthetics (i.e., reduction in particle size which minimizes “gritty” feeling upon application).
- compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present at a concentration of about 5% w/w to about 10% w/w.
- compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present at a concentration of about 3% w/w to 8% w/w.
- methods for treating a dermatological condition can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition described herein.
- FIG. 1 presents the impact of an acrylamide/sodium acryloyldimethyltaurate copolymer emulsion viscosity builder on color change.
- FIG. 2 presents the impact of an acrylamide/sodium acryloyldimethyltaurate copolymer emulsion viscosity builder on dapsone crystal growth.
- FIG. 3 presents the impact of anti-oxidants and chelating agents on color change.
- skin condition encompasses human and animal conditions, disorders, or diseases affecting skin.
- skin conditions include, but are not limited to, conditions involving skin inflammation, conditions involving sebaceous glands and hair follicles, conditions characterized by acneiform symptoms, and conditions involving skin dryness, skin thickening, skin scaling or skin flaking.
- Skin conditions that can be treated using some compositions, products and methods described herein include, but are not limited to, acne, rosacea, folliculitis, perioral dermatitis, photodamage, skin aging, psoriasis, ichtiosis, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis piralis, scars, including surgical and acne scars, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, eczema, and miliaria.
- acne encompasses skin conditions involving acneiform or acne-like symptoms.
- a skin condition characterized by follicular eruptions such as papules and pustules resembling acne
- the term “acne” is not to be limited to diseases and conditions characterized by papules and pustules, but can be characterized by a variety of symptoms.
- a particular patient having acne can be in remission, or the patient's acne can be controlled by continuing treatments, and therefore the patient can exhibit reduced symptoms or be asymptomatic. Nevertheless, continuing treatment of acne can be recommended in such a patient in order to reduce the probability of the return of the acne symptoms.
- Symptoms of acne or acne-like conditions include, but are not limited to, the appearance of various skin lesions.
- the term “lesion” is generally used to denote an infected or diseased patch of skin. A lesion can involve an infected sebaceous gland. Some lesions are more severe than others. Examples of skin lesions are comedones, macules, papules, pustules, nodules and cysts.
- the term “comedo” (plural “comedones”) is used to describe a sebaceous follicle plugged with dirt, other cells, tiny hairs, or bacteria.
- Comedones include the so-called “blackheads,” which can also refer to as “open comedones,” which have a spot or a surface that appears black. Comedones also include slightly inflamed, skin colored bumps, as well as “whiteheads,” which have a spot or a surface that appears white.
- the term “macule” generally refers to a flat spot or area of the skin with a changed color, such as a red spot.
- the term “pustule” is generally used to refer to an inflamed, pus-filled lesion, or a small inflamed elevation of the skin that is filled with pus.
- papule is generally used to refer to a small, solid, usually inflammatory elevation of the skin that does not contain pus.
- nodule is generally used to refer to an elevation of a skin that is similar to a papule but is white and dome-shaped. Colloquially, a papule, a pustule or a nodule can be referred to as “a pimple” or “a zit.”
- cyst generally refers to an abnormal membranous sac containing a liquid or semi-liquid substance containing white blood cells, dead cells, and bacteria. Cysts can be painful and extend to deeper layers of skin.
- acne can be classified or categorized into one or more types or categories, according to one or more lines of categorization, such as a predominantly observed type of symptoms, severity of condition or predominant localization. It is to be understood that classification of acne into one of the subtypes does not mean that the characteristics of the classified condition are limited to the symptoms associated with the specific type.
- Comedonal acne is characterized by the appearance of non-inflammatory lesions, such as blackheads and whiteheads.
- Localized cystic acne is characterized by appearance of a few cysts on face, chest and back.
- Diffuse cystic acne is characterized by the appearance of cysts on wide areas of face, chest and back.
- Nodular acne is characterized by the appearance of nodules.
- Nodulocystic acne is characterized by appearance of nodules and cysts.
- Acne vulgaris is a common form of acne characterized by the appearance of several types of lesions, which may appear together or separately. Individual acne lesions usually last less than two weeks but the deeper papules and nodules may persist for months.
- Acne vulgaris commonly affects adolescents, but it may also appear, persist or become more severe in adulthood. Acne vulgaris may occur on the face, chest, back and sometimes even more extensively.
- acne can be mild, moderate or severe. Mild acne is generally categorized by the appearance of with blackheads and whiteheads, but can also include papules and pustules. Moderate acne is generally characterized by appearance of more painful, deep-rooted, inflamed lesions, which can result in scarring. Severe acne is characterized by the appearance of deep-rooted inflammatory lesions, including cysts and nodules which can be painful and can produce scarring. Acne conglobata is a category of acne characterized by highly inflammatory cysts that communicate under the skin with abscesses and burrowing sinus tracts.
- rosacea fulminans is a condition that appears in females and is characterized by abrupt appearance of inflamed cysts and nodules localized on the face.
- Rosacea which can be referred to as acne rosacea, is a condition that can affects both the skin and the eyes and is characterized by redness, bumps, pimples, and, in advanced stages, thickened skin on the nose. In some classification systems, rosacea and acne are considered as separate conditions. Rosacea usually occurs on the face, although the neck and upper chest are also sometimes involved.
- Perioral dermatitis is characterized by the appearance of small tiny papules, pustules, red bumps and scaling with intense itching. It is usually localized to the surrounding area of the mouth and on the chin, or extends to involve the eyelids and the forehead.
- Gram-negative folliculitis is a bacterial infection characterized by the appearance of pustules and cysts, possibly occurring as a complication resulting from a long term antibiotic treatment of acne vulgaris.
- treatment or “treating” in reference to a skin condition generally mean “having positive effect on a skin condition” and encompass alleviation of at least one symptom of a skin condition, a reduction in the severity of the skin conditions, or delay, prevention, or inhibition of the progression of the skin condition.
- Treatment need not mean that the condition is totally cured.
- a composition or a product useful for treatment of a skin condition, or a method of treating a skin condition needs only to reduce the severity of a skin condition, reduce the severity of symptoms associated therewith, provide improvement to a patient's quality of life, or delay, prevent, or inhibit the onset of symptoms of a skin condition.
- compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present at a concentration of about 5% w/w to about 10% w/w, about 1% w/w to about 10% w/w, about 3% w/w to about 10% w/w, about 3% w/w to about 8% w/w, about 4% w/w to about 6% w/w, or about 5%.
- dapsone is present in the composition at 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, or 10.0% w/w.
- the polymeric viscosity builder is an acrylamide/sodium acryloyldimethyltaurate copolymer, and further includes isohexadecane, sorbitan oleate, water, and Polysorbate 80.
- the polymeric viscosity builder is present at a concentration of about 2% w/w to about 6% w/w.
- the polymeric viscosity builder is present at a concentration of about 3% w/w to about 5% w/w.
- the polymeric viscosity builder is present in the composition at about 4% w/w.
- diethylene glycol monoethyl ether is present at a concentration of about 25% w/w to about 40% w/w. In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 30% w/w to about 40% w/w. In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 35% w/w to about 40% w/w.
- diethylene glycol monoethyl ether is present at a concentration of about 10% w/w to about 40% w/w, about 20% w/w to about 30% w/w, or about 25%.
- compositions further including adapalene.
- adapalene is present at a concentration of about 0.1% w/w to about 0.3% w/w.
- the second solubilizing agent is selected from alcohols, glycols, esters, ethers, or silicones.
- Such second solubilizing agents include, but are not limited to, PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, benzyl alcohol, diethyl sebacate, and ethanol.
- the second solubilizing agent is propylene glycol.
- propylene glycol is present at a concentration of about 2% w/w to 8% w/w. In some embodiments, propylene glycol is present at a concentration of about 3% w/w to 7% w/w. In some embodiments, propylene glycol is present in the composition at about 5% w/w.
- the second solubilizing agent is propylene carbonate.
- propylene carbonate is present at a concentration of about 2% w/w to 8% w/w. In some embodiments, propylene carbonate is present at a concentration of about 3% w/w to 7% w/w. In some embodiments, propylene carbonate is present in the composition at about 5% w/w.
- the second solubilizing agent is ethanol. In some embodiments, ethanol is present at a concentration of about 1% w/w to about 5% w/w. In some embodiments, ethanol is present at a concentration of about 2% w/w to about 4% w/w. In some embodiments, ethanol is present in the composition at about 3% w/w.
- compositions further include methyl paraben.
- compositions further include carbomer homopolymer type C.
- carbomer homopolymer type C is present at a concentration of about 0.7% w/w to about 1.5% w/w. In other embodiments, carbomer homopolymer type C is present at a concentration of about 0.85% w/w to about 1.0% w/w.
- the compositions further include a neutralizing agent.
- the neutralizing agent is an ionic or amine buffer.
- the neutralizing agent is sodium hydroxide or triethanolamine. Use of a neutralizing agent results in compositions typically having a pH from 5.5 to 6.5.
- the compositions further include a chelating agent.
- the chelating agent is ethylene diamine tetraacetic acid (EDTA).
- EDTA is typically present in the compositions from about 0.02% w/w to about 0.04% w/w. In certain embodiments, EDTA is present in the compositions at about 0.03% w/w.
- compositions described herein are typically in the form of a gel, an emulsion, a cream, a liquid, a paste, a lotion, a nanoemulsion, a microemulsion, a reverse emulsion, or a liposomal cream.
- Embodiment 1 A composition comprising dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present in the composition at a concentration of about 3% w/w to about 10% w/w.
- Embodiment 2 The composition of embodiment 1, wherein the diethylene glycol monoethyl ether is present at a concentration of about 10% w/w to about 40% w/w.
- Embodiment 3 The composition of embodiment 1, wherein the diethylene glycol monoethyl ether is present at a concentration of about 20% w/w to about 30% w/w.
- Embodiment 4 The composition of embodiment 1, wherein the diethylene glycol monoethyl ether is present in the composition at a concentration of about 25% w/w.
- Embodiment 5 The composition of embodiment 1, further comprising adapalene.
- Embodiment 6 The composition of embodiment 5, wherein the adapalene is present at a concentration of about 0.1% w/w to about 0.3% w/w.
- Embodiment 7 The composition of embodiment 1 wherein the second solubilizing agent is selected an alcohol, a glycol, an ester, or an ether.
- Embodiment 8 The composition of embodiment 1, wherein the second solubilizing agent is PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, diethyl sebacate, or ethanol.
- the second solubilizing agent is PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, diethyl sebacate, or ethanol.
- Embodiment 9 The composition of embodiment 8, wherein the second solubilizing agent is propylene glycol.
- Embodiment 10 The composition of embodiment 9, wherein the propylene glycol is present in the composition at a concentration of about 5% w/w.
- Embodiment 11 The composition of embodiment 8, wherein the second solubilizing agent is propylene carbonate.
- Embodiment 12 The composition of embodiment 11, wherein the propylene carbonate is present in the composition at a concentration of about 5% w/w.
- Embodiment 13 The composition of embodiment 8, wherein the second solubilizing agent is ethanol.
- Embodiment 14 The composition of embodiment 13, wherein the ethanol is present in the composition at a concentration of about 3% w/w.
- Embodiment 15 The composition of embodiment 1, wherein the polymeric viscosity builder comprises an acrylamide/sodium acryloyldimethyltaurate copolymer.
- Embodiment 16 The composition of embodiment 1, wherein the polymeric viscosity builder is present at a concentration of about 2% w/w to about 6% w/w.
- Embodiment 17 The composition of embodiment 1, wherein the polymeric viscosity builder is present at a concentration of about 4% w/w.
- Embodiment 18 The composition of embodiment 1, further comprising methyl paraben.
- Embodiment 19 The composition of embodiment 1, further comprising Carbomer interpolymer type A, Carbomer interpolymer type B, or Carbomer Homopolymer Type C.
- Embodiment 20 The composition of embodiment 19, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.7% w/w to about 1.5% w/w.
- Embodiment 21 The composition of embodiment 19, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.85% w/w to about 1.5% w/w.
- Embodiment 22 The composition of embodiment 19, wherein the Carbomer interpolymer Type A is present at a concentration of about 1% w/w to 2% w/w.
- Embodiment 23 The composition of embodiment 19, wherein the Carbomer interpolymer Type B is present at a concentration of about 0.1% w/w to about 0.5% w/w.
- Embodiment 24 The composition of embodiment 1, further comprising a neutralizing agent.
- Embodiment 25 The composition of embodiment 24 wherein the neutralizing agent is NaOH or triethanolamine.
- Embodiment 26 The composition of embodiment 1 further comprising a chelating agent.
- Embodiment 27 The composition of embodiment 26, wherein the chelating agent is ethylene diamine tetraacetic acid.
- Embodiment 28 The composition of embodiment 27, wherein the ethylene diamine tetraacetic acid is present at a concentration of about 0.02% w/w to about 0.04% w/w.
- Embodiment 29 The composition of embodiment 27, wherein the ethylene diamine tetraacetic acid is present in the composition at about 0.03% w/w.
- Embodiment 30 The composition of embodiment 1 wherein the composition is in the form of a gel, a suspension, an emulsion, a cream, a liquid, a paste, a lotion, a nanoemulsion, a microemulsion, a reverse emulsion, or a liposomal cream.
- Embodiment 31 A method for treating a dermatological condition comprising administering to a subject in need thereof a therapeutically effective amount of a composition of embodiment 1.
- Embodiment 32 The method of embodiment 31 wherein the condition is acne vulgaris, rosacea, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis piralis, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, dermatitis, eczema, or miliaria.
- the condition is acne vulgaris, rosacea, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis piralis, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, dermatitis, eczema, or miliaria.
- Embodiment 33 The method of embodiment 32 wherein the condition is acne vulgaris.
- Embodiment 34 The composition of embodiment 1, 2, 3, or 4, further comprising adapalene.
- Embodiment 35 The composition of embodiment 34, wherein the adapalene is present at a concentration of about 0.1% w/w to about 0.3% w/w.
- Embodiment 36 The composition of embodiment 1, 2, 3, 4, 34, or 35, wherein the second solubilizing agent is selected an alcohol, a glycol, an ester, or an ether.
- Embodiment 37 The composition of embodiment 1, 2, 3, 4, 34, 35, or 36, wherein the second solubilizing agent is PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, diethyl sebacate, or ethanol.
- the second solubilizing agent is PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, diethyl sebacate, or ethanol.
- Embodiment 38 The composition of embodiment 37, wherein the second solubilizing agent is propylene glycol.
- Embodiment 39 The composition of embodiment 38, wherein the propylene glycol is present in the composition at a concentration of about 5% w/w.
- Embodiment 40 The composition of embodiment 37, wherein the second solubilizing agent is propylene carbonate.
- Embodiment 41 The composition of embodiment 40, wherein the propylene carbonate is present in the composition at a concentration of about 5% w/w.
- Embodiment 42 The composition of embodiment 37, wherein the second solubilizing agent is ethanol.
- Embodiment 43 The composition of embodiment 42, wherein the ethanol is present in the composition at a concentration of about 3% w/w.
- Embodiment 44 The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, or 43, wherein the polymeric viscosity builder comprises an acrylamide/sodium acryloyldimethyltaurate copolymer.
- Embodiment 45 The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, or 44, wherein the polymeric viscosity builder is present at a concentration of about 2% w/w to about 6% w/w.
- Embodiment 46 The composition of embodiment 45, wherein the polymeric viscosity builder is present at a concentration of about 4% w/w.
- Embodiment 47 The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, or 46, further comprising methyl paraben.
- Embodiment 48 The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, or 47, further comprising Carbomer interpolymer type A, Carbomer interpolymer type B, or Carbomer Homopolymer Type C.
- Embodiment 49 The composition of embodiment 48, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.7% w/w to about 1.5% w/w.
- Embodiment 50 The composition of embodiment 48, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.85% w/w to about 1.5% w/w.
- Embodiment 51 The composition of embodiment 48, wherein the Carbomer interpolymer Type A is present at a concentration of about 1% w/w to 2% w/w.
- Embodiment 52 The composition of embodiment 48, wherein the Carbomer interpolymer Type B is present at a concentration of about 0.1% w/w to about 0.5% w/w.
- Embodiment 53 The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, or 52, further comprising a neutralizing agent.
- Embodiment 54 The composition of embodiment 53 wherein the neutralizing agent is NaOH or triethanolamine.
- Embodiment 55 The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, or 54, further comprising a chelating agent.
- Embodiment 56 The composition of embodiment 55, wherein the chelating agent is ethylene diamine tetraacetic acid.
- Embodiment 57 The composition of embodiment 56, wherein the ethylene diamine tetraacetic acid is present at a concentration of about 0.02% w/w to about 0.04% w/w.
- Embodiment 58 The composition of embodiment 56, wherein the ethylene diamine tetraacetic acid is present in the composition at about 0.03% w/w.
- Embodiment 59 The composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, or 58, wherein the composition is in the form of a gel, a suspension, an emulsion, a cream, a liquid, a paste, a lotion, a nanoemulsion, a microemulsion, a reverse emulsion, or a liposomal cream.
- Embodiment 60 A method for treating a dermatological condition comprising administering to a subject in need thereof a therapeutically effective amount of a composition of embodiment 1, 2, 3, 4, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, or 59.
- Embodiment 61 The method of embodiment 60 wherein the condition is acne vulgaris, rosacea, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis piralis, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, dermatitis, eczema, or miliaria.
- Embodiment 62 The method of embodiment 60 wherein the condition is acne vulgaris.
- Table 1 lists two formulations (containing equivalent levels of diethylene glycol monoethyl ether) that show the impact of acrylamide/sodium acryloyldimethyltaurate copolymer based thickener on dapsone particle size.
- FIG. 2 presents impact of acrylamide/sodium acryloyldimethyltaurate copolymer based thickener on dapsone crystal growth.
- ENA acrylamide/sodium acryloyldimethyltaurate copolymer based thickener
- Example compositions contemplated for use as described herein are set forth in Table 2 below.
- Anti-oxidants and chelating agents such as sodium metabisulfite, citric acid and EDTA were added to formulations to help slow down or completely stop any impurity formation.
- Table 3 presents the composition of formulations tested.
- Formulation A7 with sodium metabisulfite minimized the intensity of yellow color caused by the increased solubility of dapsone in diethylene glycol monoethyl ether and maintained the low color intensity over time at accelerated condition (40° C.). See FIG. 3 for appearance of the formulations over 4 weeks.
- Table 4 presents the formulation panel summarizing other formulation options with chelating agents and antioxidants.
- compositions contemplated for use as described herein are set forth in Table 5 below.
- compositions contemplated for use as described herein are set forth in Table 6 below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. The compositions of this disclosure include dapsone and/or adapalene in a polymeric viscosity builder. Subject compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Use of the polymeric viscosity builder provides compositions with increased concentrations of diethylene glycol monoethyl ether relative to compositions without the polymeric viscosity builder.
Description
- This application is a continuation of copending U.S. patent application Ser. No. 15/698,402, filed on Sep. 7, 2017, which is a continuation of U.S. patent application Ser. No. 15/376,345, filed on Dec. 12, 2016, now abandoned, which is a continuation of U.S. patent application Ser. No. 14/885,805, filed on Oct. 16, 2015, now issued as U.S. Pat. No. 9,517,219, which is a divisional of U.S. patent application Ser. No. 14/082,955, filed on Nov. 18, 2013, now issued as U.S. Pat. No. 9,161,926, which claims the benefit of U.S. Provisional Application Ser. No. 61/728,403 filed on Nov. 20, 2012 and U.S. Provisional Application Ser. No. 61/770,768 filed on Feb. 28, 2013, all of which are incorporated by reference herein in their entirety.
- The present embodiments relate generally to compositions useful for treating a variety of dermatological conditions. In particular, some embodiments relate to dapsone and dapsone/adapalene compositions and methods for use thereof.
- Acne is a group of common skin conditions characterized by the so-called “acneiform” or acne-like skin eruptions, which can be contaminated with bacteria, such as Propionibacterium acnes, and can also be marked by inflammation. Acne tends to occur in the areas of skin where the sebaceous glands are most active, such as the face. Acne is associated with psychological trauma, and, if left untreated, can lead to scar formation and disfigurement.
- Classification and the diagnosis of various acne conditions can be complex, and even contradictory. Given this complexity and unpredictability, medication and other therapies, are often developed on a trial-and-error basis in order to determine the most effective course of treatment for a particular patient. The outcome of any particular acne treatment regimen greatly varies from patient to patient, as well as throughout treatment of a particular patient. In addition to the complexity and variability of acne conditions, treatment efficacy can be greatly affected by a patient's compliance with the treatment regimen. Patient compliance during acne treatment may be influenced by side effects, which, for topical medications, commonly include redness, itching, and skin peeling. The complexity of the drug regimen can also negatively affect patient compliance, particularly where two or more different topical medications are prescribed simultaneously. Another factor that negatively affects patient compliance is the cost of a drug regiment, which is considerably higher when multiple medications are prescribed. In some countries, acne is considered a cosmetic problem, and acne treatments are not covered by insurance plans, thus further increasing patient's treatment costs. Certain compositions for treatment of acne are available. Many of the available compositions include one active agent known to have anti-acne activity. Stability of compositions with multiple anti-acne agents can be problematic. Also, these compositions can be difficult to manufacture.
- The problems described above are not confined to the treatment or acne, but are also applicable to a variety of other skin conditions, including, but not limited, to conditions or classes of conditions with complex or unknown etiology and that are difficult to classify or diagnose, in which, nevertheless, topical application of agents are known to be effective at least in some cases. Examples of such conditions or classes of conditions include psoriasis, rosacea and ichthyosis.
- Accordingly, there is a continuing need for compositions and methods used in a treatment of a variety of skin conditions, such as acne, in which topical application is potentially effective. The compositions and methods provided herein address these and other needs in the art.
- Dapsone, (4,4′-diaminodiphenyl sulfone) is a medicament possessing several beneficial medicinal activities. Dapsone is typically administered as one of the medicinal agents used in the treatment of leprosy. Dapsone and its derivatives are also effective for treatment of bacterial infections, protozoal infections such as malaria, pneumocystis carinii, and plasmonic infections such as toxoplasmosis.
- Dapsone is also useful as an anti-inflammatory agent. It has been used to treat skin diseases characterized by the abnormal infiltration of neutrophils, such as Dermatitis herpetiformis, linear IgA dermatosis, pustular psoriasis, pyoderma gangrenosum, acne vulgaris, and Sweet's Syndrome.
- Use of topical compositions of dapsone can be problematic. Topical compositions may act as drying agents for the skin. They remove essential oils and natural skin softeners from the skin thus causing it to be dry, itch and crack. Inclusion of exogeneous skin emollients, oils and the like, however, causes phase separation and precipitation of dapsone. Use of typical emulsifiers does not solve the dapsone precipitation owing to the lowered dapsone solubility and conflicting physical characteristics of the phases of the resulting composition. In particular, topical compositions including dapsone and methods are needed that would, for example, exhibit improved effectiveness, reduced side effects, or both, when used in a particular patient with a skin condition. Such improved topical compositions including dapsone and methods of their uses are also needed to improve treatment of patients with acne or suspected acne. The present dapsone and dapsone/adapalene compositions can be useful for treating a variety of dermatological conditions. Some useful compositions include dapsone and/or adapalene in a polymeric viscosity builder. Some compositions can be adjusted to optimize the dermal delivery profile of dapsone to effectively treat dermatological conditions and improve the efficiency of pharmaceutical products applied to the skin. Diethylene glycol monoethyl ether is a solubilizer for dapsone, thereby allowing compositions to be prepared with increased solubilized concentrations of dapsone. As a result, the compositions described herein are effective in treating dermatological conditions in a subject in need thereof
- Moreover, it has been found that use of a polymeric viscosity builder minimizes the intensity of yellowing of the composition caused by the increased solubility of dapsone in diethylene glycol monoethyl ether. In addition, the polymeric viscosity builder influences dapsone crystallization. This, in turn, results in compositions with improved aesthetics (i.e., reduction in particle size which minimizes “gritty” feeling upon application).
- In one embodiment, there are provided compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present at a concentration of about 5% w/w to about 10% w/w.
- In one embodiment, there are provided compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present at a concentration of about 3% w/w to 8% w/w.
- In another embodiment, there are provided methods for treating a dermatological condition. Such methods can be performed, for example, by administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition described herein.
-
FIG. 1 presents the impact of an acrylamide/sodium acryloyldimethyltaurate copolymer emulsion viscosity builder on color change. -
FIG. 2 presents the impact of an acrylamide/sodium acryloyldimethyltaurate copolymer emulsion viscosity builder on dapsone crystal growth. -
FIG. 3 presents the impact of anti-oxidants and chelating agents on color change. - It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and do not restrict the claims. As used herein, the use of the singular includes the plural unless specifically stated otherwise. As used herein, “or” means “and/or” unless stated otherwise. Furthermore, use of the term “including” as well as other forms, such as “includes,” and “included,” is not limiting. The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
- Some embodiments include compositions and products for treatment of skin conditions and methods of treating skin conditions. The term “skin condition” as used herein encompasses human and animal conditions, disorders, or diseases affecting skin. Such skin conditions include, but are not limited to, conditions involving skin inflammation, conditions involving sebaceous glands and hair follicles, conditions characterized by acneiform symptoms, and conditions involving skin dryness, skin thickening, skin scaling or skin flaking. Skin conditions that can be treated using some compositions, products and methods described herein include, but are not limited to, acne, rosacea, folliculitis, perioral dermatitis, photodamage, skin aging, psoriasis, ichtiosis, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis piralis, scars, including surgical and acne scars, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, eczema, and miliaria.
- The term “acne,” as used herein, encompasses skin conditions involving acneiform or acne-like symptoms. For example, a skin condition characterized by follicular eruptions, such as papules and pustules resembling acne, can be categorized as acne. It is to be understood that the term “acne” is not to be limited to diseases and conditions characterized by papules and pustules, but can be characterized by a variety of symptoms. It is also to be understood that a particular patient having acne can be in remission, or the patient's acne can be controlled by continuing treatments, and therefore the patient can exhibit reduced symptoms or be asymptomatic. Nevertheless, continuing treatment of acne can be recommended in such a patient in order to reduce the probability of the return of the acne symptoms.
- Symptoms of acne or acne-like conditions include, but are not limited to, the appearance of various skin lesions. The term “lesion” is generally used to denote an infected or diseased patch of skin. A lesion can involve an infected sebaceous gland. Some lesions are more severe than others. Examples of skin lesions are comedones, macules, papules, pustules, nodules and cysts. The term “comedo” (plural “comedones”) is used to describe a sebaceous follicle plugged with dirt, other cells, tiny hairs, or bacteria. Comedones include the so-called “blackheads,” which can also refer to as “open comedones,” which have a spot or a surface that appears black. Comedones also include slightly inflamed, skin colored bumps, as well as “whiteheads,” which have a spot or a surface that appears white. The term “macule” generally refers to a flat spot or area of the skin with a changed color, such as a red spot. The term “pustule” is generally used to refer to an inflamed, pus-filled lesion, or a small inflamed elevation of the skin that is filled with pus. The term “papule” is generally used to refer to a small, solid, usually inflammatory elevation of the skin that does not contain pus. The term “nodule” is generally used to refer to an elevation of a skin that is similar to a papule but is white and dome-shaped. Colloquially, a papule, a pustule or a nodule can be referred to as “a pimple” or “a zit.” The term “cyst” generally refers to an abnormal membranous sac containing a liquid or semi-liquid substance containing white blood cells, dead cells, and bacteria. Cysts can be painful and extend to deeper layers of skin.
- In dermatological science and dermatological and cosmetology practice, acne can be classified or categorized into one or more types or categories, according to one or more lines of categorization, such as a predominantly observed type of symptoms, severity of condition or predominant localization. It is to be understood that classification of acne into one of the subtypes does not mean that the characteristics of the classified condition are limited to the symptoms associated with the specific type.
- Comedonal acne is characterized by the appearance of non-inflammatory lesions, such as blackheads and whiteheads. Localized cystic acne is characterized by appearance of a few cysts on face, chest and back. Diffuse cystic acne is characterized by the appearance of cysts on wide areas of face, chest and back. Nodular acne is characterized by the appearance of nodules. Nodulocystic acne is characterized by appearance of nodules and cysts. Acne vulgaris is a common form of acne characterized by the appearance of several types of lesions, which may appear together or separately. Individual acne lesions usually last less than two weeks but the deeper papules and nodules may persist for months. Acne vulgaris commonly affects adolescents, but it may also appear, persist or become more severe in adulthood. Acne vulgaris may occur on the face, chest, back and sometimes even more extensively.
- Depending on severity, acne can be mild, moderate or severe. Mild acne is generally categorized by the appearance of with blackheads and whiteheads, but can also include papules and pustules. Moderate acne is generally characterized by appearance of more painful, deep-rooted, inflamed lesions, which can result in scarring. Severe acne is characterized by the appearance of deep-rooted inflammatory lesions, including cysts and nodules which can be painful and can produce scarring. Acne conglobata is a category of acne characterized by highly inflammatory cysts that communicate under the skin with abscesses and burrowing sinus tracts.
- Some other skin conditions exhibiting acne-like symptoms which can be treated by the compositions and methods described herein are discussed below. Pyoderma faciale, also known as rosacea fulminans, is a condition that appears in females and is characterized by abrupt appearance of inflamed cysts and nodules localized on the face. Rosacea, which can be referred to as acne rosacea, is a condition that can affects both the skin and the eyes and is characterized by redness, bumps, pimples, and, in advanced stages, thickened skin on the nose. In some classification systems, rosacea and acne are considered as separate conditions. Rosacea usually occurs on the face, although the neck and upper chest are also sometimes involved. A mild degree of eye (ocular) involvement occurs in more than fifty percent of people with rosacea. Perioral dermatitis is characterized by the appearance of small tiny papules, pustules, red bumps and scaling with intense itching. It is usually localized to the surrounding area of the mouth and on the chin, or extends to involve the eyelids and the forehead. Gram-negative folliculitis is a bacterial infection characterized by the appearance of pustules and cysts, possibly occurring as a complication resulting from a long term antibiotic treatment of acne vulgaris.
- As used herein, the terms “treatment” or “treating” in reference to a skin condition generally mean “having positive effect on a skin condition” and encompass alleviation of at least one symptom of a skin condition, a reduction in the severity of the skin conditions, or delay, prevention, or inhibition of the progression of the skin condition.
- Treatment need not mean that the condition is totally cured. A composition or a product useful for treatment of a skin condition, or a method of treating a skin condition, needs only to reduce the severity of a skin condition, reduce the severity of symptoms associated therewith, provide improvement to a patient's quality of life, or delay, prevent, or inhibit the onset of symptoms of a skin condition.
- In one embodiment, there are provided compositions including dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present at a concentration of about 5% w/w to about 10% w/w, about 1% w/w to about 10% w/w, about 3% w/w to about 10% w/w, about 3% w/w to about 8% w/w, about 4% w/w to about 6% w/w, or about 5%. In certain embodiments, dapsone is present in the composition at 5.0%, 5.5%, 6.0%, 6.5%, 7.0%, 7.5%, 8.0%, 8.5%, 9.0%, 9.5%, or 10.0% w/w.
- In some embodiments, the polymeric viscosity builder is an acrylamide/sodium acryloyldimethyltaurate copolymer, and further includes isohexadecane, sorbitan oleate, water, and Polysorbate 80. In some embodiments, the polymeric viscosity builder is present at a concentration of about 2% w/w to about 6% w/w. In some embodiments, the polymeric viscosity builder is present at a concentration of about 3% w/w to about 5% w/w. In some embodiments, the polymeric viscosity builder is present in the composition at about 4% w/w.
- In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 25% w/w to about 40% w/w. In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 30% w/w to about 40% w/w. In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 35% w/w to about 40% w/w.
- In some embodiments, diethylene glycol monoethyl ether is present at a concentration of about 10% w/w to about 40% w/w, about 20% w/w to about 30% w/w, or about 25%.
- In another embodiment, there are provided compositions further including adapalene. In some embodiments, adapalene is present at a concentration of about 0.1% w/w to about 0.3% w/w.
- In some embodiments, the second solubilizing agent is selected from alcohols, glycols, esters, ethers, or silicones. Such second solubilizing agents include, but are not limited to, PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, benzyl alcohol, diethyl sebacate, and ethanol.
- In certain embodiments, the second solubilizing agent is propylene glycol. In some embodiments, propylene glycol is present at a concentration of about 2% w/w to 8% w/w. In some embodiments, propylene glycol is present at a concentration of about 3% w/w to 7% w/w. In some embodiments, propylene glycol is present in the composition at about 5% w/w.
- In certain embodiments, the second solubilizing agent is propylene carbonate. In some embodiments, propylene carbonate is present at a concentration of about 2% w/w to 8% w/w. In some embodiments, propylene carbonate is present at a concentration of about 3% w/w to 7% w/w. In some embodiments, propylene carbonate is present in the composition at about 5% w/w.
- In certain embodiments, the second solubilizing agent is ethanol. In some embodiments, ethanol is present at a concentration of about 1% w/w to about 5% w/w. In some embodiments, ethanol is present at a concentration of about 2% w/w to about 4% w/w. In some embodiments, ethanol is present in the composition at about 3% w/w.
- In some embodiments, the compositions further include methyl paraben.
- In other embodiments, the compositions further include carbomer homopolymer type C. In some embodiments, carbomer homopolymer type C is present at a concentration of about 0.7% w/w to about 1.5% w/w. In other embodiments, carbomer homopolymer type C is present at a concentration of about 0.85% w/w to about 1.0% w/w.
- In some embodiments, the compositions further include a neutralizing agent. In certain embodiments, the neutralizing agent is an ionic or amine buffer. In certain embodiments, the neutralizing agent is sodium hydroxide or triethanolamine. Use of a neutralizing agent results in compositions typically having a pH from 5.5 to 6.5.
- In some embodiments, the compositions further include a chelating agent. In some embodiments, the chelating agent is ethylene diamine tetraacetic acid (EDTA). EDTA is typically present in the compositions from about 0.02% w/w to about 0.04% w/w. In certain embodiments, EDTA is present in the compositions at about 0.03% w/w.
- Compositions described herein are typically in the form of a gel, an emulsion, a cream, a liquid, a paste, a lotion, a nanoemulsion, a microemulsion, a reverse emulsion, or a liposomal cream.
- The following embodiments are specifically contemplated herein.
- Embodiment 1. A composition comprising dapsone, a first solubilizing agent which is diethylene glycol monoethyl ether, optionally at least one second solubilizing agent, a polymeric viscosity builder, and water, wherein the dapsone is present in the composition at a concentration of about 3% w/w to about 10% w/w.
- Embodiment 2. The composition of embodiment 1, wherein the diethylene glycol monoethyl ether is present at a concentration of about 10% w/w to about 40% w/w.
- Embodiment 3. The composition of embodiment 1, wherein the diethylene glycol monoethyl ether is present at a concentration of about 20% w/w to about 30% w/w.
- Embodiment 4. The composition of embodiment 1, wherein the diethylene glycol monoethyl ether is present in the composition at a concentration of about 25% w/w.
- Embodiment 5. The composition of embodiment 1, further comprising adapalene.
- Embodiment 6. The composition of embodiment 5, wherein the adapalene is present at a concentration of about 0.1% w/w to about 0.3% w/w.
- Embodiment 7. The composition of embodiment 1 wherein the second solubilizing agent is selected an alcohol, a glycol, an ester, or an ether.
- Embodiment 8. The composition of embodiment 1, wherein the second solubilizing agent is PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, diethyl sebacate, or ethanol.
- Embodiment 9. The composition of embodiment 8, wherein the second solubilizing agent is propylene glycol.
- Embodiment 10. The composition of embodiment 9, wherein the propylene glycol is present in the composition at a concentration of about 5% w/w.
- Embodiment 11. The composition of embodiment 8, wherein the second solubilizing agent is propylene carbonate.
- Embodiment 12. The composition of embodiment 11, wherein the propylene carbonate is present in the composition at a concentration of about 5% w/w.
- Embodiment 13. The composition of embodiment 8, wherein the second solubilizing agent is ethanol.
- Embodiment 14. The composition of embodiment 13, wherein the ethanol is present in the composition at a concentration of about 3% w/w.
- Embodiment 15. The composition of embodiment 1, wherein the polymeric viscosity builder comprises an acrylamide/sodium acryloyldimethyltaurate copolymer.
- Embodiment 16. The composition of embodiment 1, wherein the polymeric viscosity builder is present at a concentration of about 2% w/w to about 6% w/w.
- Embodiment 17. The composition of embodiment 1, wherein the polymeric viscosity builder is present at a concentration of about 4% w/w.
- Embodiment 18. The composition of embodiment 1, further comprising methyl paraben.
- Embodiment 19. The composition of embodiment 1, further comprising Carbomer interpolymer type A, Carbomer interpolymer type B, or Carbomer Homopolymer Type C.
- Embodiment 20. The composition of embodiment 19, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.7% w/w to about 1.5% w/w.
- Embodiment 21. The composition of embodiment 19, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.85% w/w to about 1.5% w/w.
- Embodiment 22. The composition of embodiment 19, wherein the Carbomer interpolymer Type A is present at a concentration of about 1% w/w to 2% w/w.
- Embodiment 23. The composition of embodiment 19, wherein the Carbomer interpolymer Type B is present at a concentration of about 0.1% w/w to about 0.5% w/w.
- Embodiment 24. The composition of embodiment 1, further comprising a neutralizing agent.
- Embodiment 25. The composition of embodiment 24 wherein the neutralizing agent is NaOH or triethanolamine.
- Embodiment 26. The composition of embodiment 1 further comprising a chelating agent.
- Embodiment 27. The composition of embodiment 26, wherein the chelating agent is ethylene diamine tetraacetic acid.
- Embodiment 28. The composition of embodiment 27, wherein the ethylene diamine tetraacetic acid is present at a concentration of about 0.02% w/w to about 0.04% w/w.
- Embodiment 29. The composition of embodiment 27, wherein the ethylene diamine tetraacetic acid is present in the composition at about 0.03% w/w.
- Embodiment 30. The composition of embodiment 1 wherein the composition is in the form of a gel, a suspension, an emulsion, a cream, a liquid, a paste, a lotion, a nanoemulsion, a microemulsion, a reverse emulsion, or a liposomal cream.
- Embodiment 31. A method for treating a dermatological condition comprising administering to a subject in need thereof a therapeutically effective amount of a composition of embodiment 1.
- Embodiment 32. The method of embodiment 31 wherein the condition is acne vulgaris, rosacea, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis piralis, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, dermatitis, eczema, or miliaria.
- Embodiment 33. The method of embodiment 32 wherein the condition is acne vulgaris.
- Embodiment 34. The composition of embodiment 1, 2, 3, or 4, further comprising adapalene.
- Embodiment 35. The composition of embodiment 34, wherein the adapalene is present at a concentration of about 0.1% w/w to about 0.3% w/w.
- Embodiment 36. The composition of embodiment 1, 2, 3, 4, 34, or 35, wherein the second solubilizing agent is selected an alcohol, a glycol, an ester, or an ether.
- Embodiment 37. The composition of embodiment 1, 2, 3, 4, 34, 35, or 36, wherein the second solubilizing agent is PEG 400, lactic acid, dimethyl isosorbide, propylene glycol, propylene carbonate, hexylene glycol, isostearyl alcohol, diethyl sebacate, or ethanol.
- Embodiment 38. The composition of embodiment 37, wherein the second solubilizing agent is propylene glycol.
- Embodiment 39. The composition of embodiment 38, wherein the propylene glycol is present in the composition at a concentration of about 5% w/w.
- Embodiment 40. The composition of embodiment 37, wherein the second solubilizing agent is propylene carbonate.
-
Embodiment 41. The composition of embodiment 40, wherein the propylene carbonate is present in the composition at a concentration of about 5% w/w. -
Embodiment 42. The composition of embodiment 37, wherein the second solubilizing agent is ethanol. -
Embodiment 43. The composition ofembodiment 42, wherein the ethanol is present in the composition at a concentration of about 3% w/w. - Embodiment 44. The composition of
embodiment - Embodiment 45. The composition of
embodiment - Embodiment 46. The composition of embodiment 45, wherein the polymeric viscosity builder is present at a concentration of about 4% w/w.
- Embodiment 47. The composition of
embodiment - Embodiment 48. The composition of
embodiment - Embodiment 49. The composition of embodiment 48, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.7% w/w to about 1.5% w/w.
- Embodiment 50. The composition of embodiment 48, wherein the Carbomer Homopolymer Type C is present at a concentration of about 0.85% w/w to about 1.5% w/w.
- Embodiment 51. The composition of embodiment 48, wherein the Carbomer interpolymer Type A is present at a concentration of about 1% w/w to 2% w/w.
- Embodiment 52. The composition of embodiment 48, wherein the Carbomer interpolymer Type B is present at a concentration of about 0.1% w/w to about 0.5% w/w.
- Embodiment 53. The composition of
embodiment - Embodiment 54. The composition of embodiment 53 wherein the neutralizing agent is NaOH or triethanolamine.
- Embodiment 55. The composition of
embodiment - Embodiment 56. The composition of embodiment 55, wherein the chelating agent is ethylene diamine tetraacetic acid.
- Embodiment 57. The composition of embodiment 56, wherein the ethylene diamine tetraacetic acid is present at a concentration of about 0.02% w/w to about 0.04% w/w.
- Embodiment 58. The composition of embodiment 56, wherein the ethylene diamine tetraacetic acid is present in the composition at about 0.03% w/w.
- Embodiment 59. The composition of
embodiment - Embodiment 60. A method for treating a dermatological condition comprising administering to a subject in need thereof a therapeutically effective amount of a composition of
embodiment - Embodiment 61. The method of embodiment 60 wherein the condition is acne vulgaris, rosacea, atopic dermatitis, treatment of chronic wounds, bed sores, keratosis piralis, sebaceous cysts, inflammatory dermatoses, post inflammatory hyperpigmentation, eczema, xerosis, pruritis, lichen planus, nodular prurigo, dermatitis, eczema, or miliaria.
- Embodiment 62. The method of embodiment 60 wherein the condition is acne vulgaris.
- The following examples are intended only to illustrate the some embodiments and should in no way be construed as limiting the claims.
- Table 1 lists two formulations (containing equivalent levels of diethylene glycol monoethyl ether) that show the impact of acrylamide/sodium acryloyldimethyltaurate copolymer based thickener on dapsone particle size.
FIG. 2 presents impact of acrylamide/sodium acryloyldimethyltaurate copolymer based thickener on dapsone crystal growth. The microscopic image of ENA (30% diethylene glycol monoethyl ether, 4% acrylamide/sodium acryloyldimethyltaurate copolymer based thickener) in comparison to ENC (30% diethylene glycol monoethyl ether, 1% Carbopol 980) shows a clear difference in particle size of the dapsone. Larger crystals were observed in the sample with carbomer homopolymer type C (ENC vs. ENA). -
TABLE 1 Formulations Tested For Dapsone Crystal Size Formulation # ENA ENC Dapsone 7.5 7.5 Diethylene glycol monoethyl ether 30 30 Carbomer homopolymer type C. — 1 acrylamide/sodium 4 — acryloyldimethyltaurate copolymer based thickener Methyl paraben 0.2 0.2 pH adjusting solution pH 5.5-7 pH 5.5-7 Purified Water Q.S 100 Q.S 100 - Example compositions contemplated for use as described herein are set forth in Table 2 below.
-
TABLE 2 Composition # 1 2 3 4 5 6 7 8 9 10 Dapsone 5-10 Adapalene — 0.1-0.3 Diethylene glycol 30 35 40 30 35 30 35 40 30 35 monoethyl ether Carbomer — 0.85-1.5 — — — 0.85-1.5 homopolymer type C Acrylamide/sodium 4 — 4 — acryloyldimethyl- taurate copolymer emulsion Methyl paraben 0.2 NaOH/pH adjusting pH 5.5-6.5 solution Purified Water Q.S 100 - Anti-oxidants and chelating agents such as sodium metabisulfite, citric acid and EDTA were added to formulations to help slow down or completely stop any impurity formation. Table 3 presents the composition of formulations tested. Formulation A7 with sodium metabisulfite minimized the intensity of yellow color caused by the increased solubility of dapsone in diethylene glycol monoethyl ether and maintained the low color intensity over time at accelerated condition (40° C.). See
FIG. 3 for appearance of the formulations over 4 weeks. Table 4 presents the formulation panel summarizing other formulation options with chelating agents and antioxidants. -
TABLE 3 Compositions Tested containing Antioxidants or Chelating Agents Composition # A5 A6 A7 Dapsone 7.5 Diethylene glycol monoethyl ether 35 40 35 carbomer homopolymer type C 1.25 — 1.25 Acrylamide/sodium — 4 — acryloyldimethyltaurate copolymer emulsion EDTA 0.05 — Anhydrous Citric Acid 0.1 — Sodium Metabisulfite — 0.2 Methyl paraben 0.17 0.2 Propyl paraben 0.03 — NaOH/pH adjusting solution pH 5.5-6.5 Purified Water Q.S 100 -
TABLE 4 Formulation panel summarizing other formulation options Composition # 1 2 3 4 5 6 7 8 9 10 Dapsone 5-10 Adapalene — 0.1-0.3 Diethylene glycol 30 35 40 30 35 30 35 40 30 35 monoethyl ether carbomer — 0.85-1.5 — 0.85-1.5 homopolymer type C Acrylamide/sodium 4 — 4 — Acryloyldimethyl- taurate copolymer emulsion EDTA 0-0.1 Citric Acid 0-0.1 Sodium Metabisulfite 0-0.5 Methyl paraben 0.2 NaOH/pH adjusting pH 5.5-6.5 solution Purified Water Q.S 100 - Additional example compositions contemplated for use as described herein are set forth in Table 5 below.
-
TABLE 5 Additional examples containing alternate neutralizer % w/w Materials 5-1 5-2 5-3 5-4 5-5 5-6 Dapsone 7.5 Adapalene — 0.3 — Diethylene glycol monoethyl ether 30 35 40 30 40 25 carbomer homopolymer type C 1 Methylparaben 0.2 Triethanolamine (TEA) Q.S. pH 5.5-6.5 Hydrochloric Acid Q.S pH 5.5-6.5 Purified Water q.s.a.d. 100 - Additional example compositions contemplated for use as described herein are set forth in Table 6 below.
-
TABLE 6 Additional examples (containing co-solvents, stabilizer, and alternate thickener) % w/w Materials 6-1 6-2 6-3 6-4 6-5 6-6 Dapsone 7.5 10 7.5 Adapalene — 0.3 Diethylene glycol monoethyl ether 25 35 35 25 30 40 Propylene glycol 5 Propylene Carbonate 5 Ethanol (absolute) 3 — 3 EDTA 0.03 Carbomer Interpolymer Type A — 1.5 Carbomer Interpolymer Type B — 0.3 Acrylamide/sodium 4 — 4 acryloyldimethyltaurate Methyl Paraben 0.2 Triethanolamine — Q.S. pH 5.5-6.5 Purified Water q.s.a.d. 100 indicates data missing or illegible when filed - Another useful composition is depicted in Table 7.
-
TABLE 7 Amount Ingredient (% w/w) Dapsone 5-8 Adapalene 0.1-0.3 Diethylene glycol monoethyl ether 40.00 Propylene glycol 5.00 Ethanol (absolute) 3.00 Ethylene Diamine Tetraacetic acid 0.03 (EDTA) Methyl Paraben 0.20 Sepineo P 600 4.00 Purified Water Q.S. - Another useful composition is depicted in Table 8.
-
TABLE 8 Amount Ingredient (% w/w) Dapsone 5.0 Diethylene glycol monoethyl ether 25 Methyl Paraben 0.2 Carbopol 980 0.85 Sodium Hydroxide 0.2 Purified Water Q.S. - While this some embodiments have been described with respect to these specific examples, it is understood that other modifications and variations are possible without departing from the spirit of the invention. Each and every reference identified herein is incorporated by reference in its entirety.
Claims (2)
1-12. (canceled)
13. A method of treating acne vulagaris comprising administering to a subject in need thereof a therapeutically effective amount of topical pharmaceutical composition comprising:
7.5% w/w dapsone;
about 30% w/w diethylene glycol monoethyl ether;
about 4% w/w of a polymeric viscosity builder comprising acrylamide/sodium acryloyldimethyl taurate copolymer;
0.2% w/w methyl paraben; and water;
wherein the dapsone is the sole active agent for the treatment of acne in the composition.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/654,061 US20220184002A1 (en) | 2012-11-20 | 2022-03-08 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261728403P | 2012-11-20 | 2012-11-20 | |
US201361770768P | 2013-02-28 | 2013-02-28 | |
US14/082,955 US9161926B2 (en) | 2012-11-20 | 2013-11-18 | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
US14/885,805 US9517219B2 (en) | 2012-11-20 | 2015-10-16 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/376,345 US20170087102A1 (en) | 2012-11-20 | 2016-12-12 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/698,402 US20170367999A1 (en) | 2012-11-20 | 2017-09-07 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/966,810 US11273132B2 (en) | 2012-11-20 | 2018-04-30 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US17/654,061 US20220184002A1 (en) | 2012-11-20 | 2022-03-08 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/966,810 Continuation US11273132B2 (en) | 2012-11-20 | 2018-04-30 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220184002A1 true US20220184002A1 (en) | 2022-06-16 |
Family
ID=49667632
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/082,955 Active US9161926B2 (en) | 2012-11-20 | 2013-11-18 | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
US14/885,805 Active US9517219B2 (en) | 2012-11-20 | 2015-10-16 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/140,109 Abandoned US20160243065A1 (en) | 2012-11-20 | 2016-04-27 | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
US15/376,345 Abandoned US20170087102A1 (en) | 2012-11-20 | 2016-12-12 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/697,252 Abandoned US20170360729A1 (en) | 2012-11-20 | 2017-09-06 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/698,402 Abandoned US20170367999A1 (en) | 2012-11-20 | 2017-09-07 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/966,810 Active US11273132B2 (en) | 2012-11-20 | 2018-04-30 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/984,657 Active US11116733B2 (en) | 2012-11-20 | 2018-05-21 | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
US17/654,061 Abandoned US20220184002A1 (en) | 2012-11-20 | 2022-03-08 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Family Applications Before (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/082,955 Active US9161926B2 (en) | 2012-11-20 | 2013-11-18 | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
US14/885,805 Active US9517219B2 (en) | 2012-11-20 | 2015-10-16 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/140,109 Abandoned US20160243065A1 (en) | 2012-11-20 | 2016-04-27 | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
US15/376,345 Abandoned US20170087102A1 (en) | 2012-11-20 | 2016-12-12 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/697,252 Abandoned US20170360729A1 (en) | 2012-11-20 | 2017-09-06 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/698,402 Abandoned US20170367999A1 (en) | 2012-11-20 | 2017-09-07 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/966,810 Active US11273132B2 (en) | 2012-11-20 | 2018-04-30 | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
US15/984,657 Active US11116733B2 (en) | 2012-11-20 | 2018-05-21 | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
Country Status (16)
Country | Link |
---|---|
US (9) | US9161926B2 (en) |
EP (1) | EP2922528B1 (en) |
JP (2) | JP6285946B2 (en) |
KR (2) | KR20150085069A (en) |
CN (1) | CN105246457B (en) |
AU (2) | AU2013348247A1 (en) |
BR (1) | BR112015011673B1 (en) |
CA (1) | CA2890224C (en) |
DK (1) | DK2922528T3 (en) |
ES (1) | ES2644342T3 (en) |
HK (1) | HK1214516A1 (en) |
HU (1) | HUE035940T2 (en) |
MX (1) | MX362520B (en) |
PL (1) | PL2922528T3 (en) |
RU (1) | RU2638815C2 (en) |
WO (1) | WO2014081674A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014081674A1 (en) * | 2012-11-20 | 2014-05-30 | Allergan, Inc. | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
KR20180073686A (en) * | 2015-11-04 | 2018-07-02 | 알러간, 인코포레이티드 | Treatment of imaginary acne using topical dapsone composition |
CN105769892A (en) * | 2016-04-21 | 2016-07-20 | 蔡敏 | Skin care solution for treating chicken pox and preparation method for skin care solution |
CN110430872A (en) * | 2017-02-15 | 2019-11-08 | 博塔尼克斯制药有限公司 | The composition for treating acne |
US20180360917A1 (en) * | 2017-06-15 | 2018-12-20 | Apicore Llc | Sincalide formulations and methods of use |
KR101959524B1 (en) * | 2018-09-19 | 2019-03-18 | 주식회사 우신라보타치 | Adhesive cataplasma system for iontophoresis comprising lidocaine |
WO2022109626A1 (en) * | 2020-11-23 | 2022-05-27 | Dermavant Sciences GmbH | Gel, ointment, and foam formulations of tapinarof and methods of use |
US20240108609A1 (en) | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11116733B2 (en) * | 2012-11-20 | 2021-09-14 | Almirall, Llc | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3419009A1 (en) | 1984-05-22 | 1985-11-28 | Dr. Karl Thomae Gmbh, 7950 Biberach | NEW SUBSTITUTED TO (4-AMINOPHENYL) SULPHONES, THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS |
US5532219A (en) * | 1991-04-23 | 1996-07-02 | The University Of British Columbia | Dapsone and promin for the treatment of dementia |
US20030157036A1 (en) | 2002-02-20 | 2003-08-21 | Osborne David W. | Topical dapsone for the treatment of acne |
US5863560A (en) | 1996-09-11 | 1999-01-26 | Virotex Corporation | Compositions and methods for topical application of therapeutic agents |
US5989571A (en) * | 1997-07-23 | 1999-11-23 | Millenium Pharmaceutical Technologies, Inc. | Contact dermatitis pharmaceutical preparation with anti-histamine and anti-inflammatory |
US7820186B2 (en) | 2001-12-21 | 2010-10-26 | Galderma Research & Development | Gel composition for once-daily treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
EP1663142A2 (en) | 2003-06-23 | 2006-06-07 | MacroChem Corporation | Compositons and methods for topical administration |
US20060204526A1 (en) | 2003-08-13 | 2006-09-14 | Lathrop Robert W | Emulsive composition containing Dapsone |
EP1675563A4 (en) * | 2003-08-13 | 2009-07-15 | Qlt Usa Inc | Emulsive composition containing dapsone |
WO2006002690A1 (en) * | 2004-07-07 | 2006-01-12 | Lundbeck Pharmaceuticals Italy S.P.A. | Process for synthesis of 4-4'-diamino-diphenyl-sulfone |
FR2903603B1 (en) * | 2006-07-13 | 2009-03-20 | Galderma Res & Dev S N C Snc | COMBINATION OF ADAPALENE AND BENZOLEO PEROXIDE IN THE TREATMENT OF ACNE |
EP2097075A1 (en) * | 2006-11-20 | 2009-09-09 | Galderma Research & Development, S.N.C. | Use of adapalene for modulating the expression of cd1d or il-10 |
US20090022818A1 (en) | 2007-07-12 | 2009-01-22 | Amcol International Corporation | High-foaming, viscous cleanser composition with a skin care agent |
WO2009061298A1 (en) * | 2007-11-07 | 2009-05-14 | Qlt Usa, Inc. | Topical treatment with dapsone in g6pd-deficient patients |
CN105287484A (en) | 2007-11-30 | 2016-02-03 | 盖尔德马研究及发展公司 | Compositions containing naphthoic acid derivative, benzoyl peroxide and film-forming agent |
FR2926218B1 (en) | 2008-01-10 | 2010-08-13 | Galderma Res & Dev | COMPOSITION COMPRISING RETINOID AND DISPERSE BENZOYL PEROXIDE. |
WO2009108147A1 (en) * | 2008-02-27 | 2009-09-03 | Qlt Usa, Inc. | Dapsone to treat rosascea |
US20100029781A1 (en) | 2008-06-04 | 2010-02-04 | Morris Jerome A | Methods for preparation of anti-acne formulation and compositions prepared thereby |
WO2010072958A2 (en) | 2008-12-23 | 2010-07-01 | Galderma S.A. | Topical pharmaceutical composition containing a water-sensitive active principle |
EP2405886B8 (en) * | 2009-03-11 | 2017-11-01 | ISP Investments LLC | Topical personal care and pharmaceutical compositions and uses thereof |
JP2012520267A (en) * | 2009-03-13 | 2012-09-06 | デベヴェ・テクノロジーズ | How to treat eczema |
RU2012104572A (en) | 2009-07-30 | 2013-09-10 | Аллерган, Инк. | DAPSON COMBINATION WITH ADAPALEN |
US20110117182A1 (en) | 2009-07-30 | 2011-05-19 | Allergan, Inc. | Combination of dapsone with other anti-acne agents |
-
2013
- 2013-11-18 WO PCT/US2013/070613 patent/WO2014081674A1/en active Application Filing
- 2013-11-18 CA CA2890224A patent/CA2890224C/en active Active
- 2013-11-18 KR KR1020157016127A patent/KR20150085069A/en active Application Filing
- 2013-11-18 EP EP13795979.7A patent/EP2922528B1/en active Active
- 2013-11-18 HU HUE13795979A patent/HUE035940T2/en unknown
- 2013-11-18 JP JP2015543097A patent/JP6285946B2/en active Active
- 2013-11-18 KR KR1020217012602A patent/KR102291448B1/en active IP Right Grant
- 2013-11-18 AU AU2013348247A patent/AU2013348247A1/en not_active Abandoned
- 2013-11-18 RU RU2015123207A patent/RU2638815C2/en active
- 2013-11-18 BR BR112015011673-6A patent/BR112015011673B1/en active IP Right Grant
- 2013-11-18 ES ES13795979.7T patent/ES2644342T3/en active Active
- 2013-11-18 MX MX2015006396A patent/MX362520B/en active IP Right Grant
- 2013-11-18 CN CN201380070519.0A patent/CN105246457B/en active Active
- 2013-11-18 DK DK13795979.7T patent/DK2922528T3/en active
- 2013-11-18 US US14/082,955 patent/US9161926B2/en active Active
- 2013-11-18 PL PL13795979T patent/PL2922528T3/en unknown
-
2015
- 2015-10-16 US US14/885,805 patent/US9517219B2/en active Active
-
2016
- 2016-03-04 HK HK16102488.7A patent/HK1214516A1/en unknown
- 2016-04-27 US US15/140,109 patent/US20160243065A1/en not_active Abandoned
- 2016-12-12 US US15/376,345 patent/US20170087102A1/en not_active Abandoned
-
2017
- 2017-09-06 US US15/697,252 patent/US20170360729A1/en not_active Abandoned
- 2017-09-07 US US15/698,402 patent/US20170367999A1/en not_active Abandoned
-
2018
- 2018-02-02 JP JP2018017578A patent/JP6644817B2/en active Active
- 2018-04-30 US US15/966,810 patent/US11273132B2/en active Active
- 2018-05-21 US US15/984,657 patent/US11116733B2/en active Active
- 2018-08-10 AU AU2018214139A patent/AU2018214139B2/en active Active
-
2022
- 2022-03-08 US US17/654,061 patent/US20220184002A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11116733B2 (en) * | 2012-11-20 | 2021-09-14 | Almirall, Llc | Topical dapsone and dapsone/adaplene compositions and methods for use thereof |
US11273132B2 (en) * | 2012-11-20 | 2022-03-15 | Almirall, Llc | Topical dapsone and dapsone/adapalene compositions and methods for use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220184002A1 (en) | Topical dapsone and dapsone/adapalene compositions and methods for use thereof | |
US20210162049A1 (en) | Retinoid topical compositions and methods for treating skin conditions | |
US20170119703A1 (en) | Methods of treatment of acne vulgaris using topical dapsone compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: ALMIRALL, LLC, PENNSYLVANIA Free format text: ASSIGNEE CHANGE OF ADDRESS;ASSIGNOR:ALMIRALL, LLC;REEL/FRAME:064858/0601 Effective date: 20210802 |